CARsgen Therapeutics Holdings Ltd. has announced that the abstract of their research results on SATRI-CEL for adjuvant therapy of pancreatic cancer has been accepted for poster presentation at the ESMO Congress 2025. The study focuses on the application of SATRI-CEL, a CAR T-cell therapy, aimed at targeting solid tumors such as pancreatic cancer. The presentation is scheduled for a future date, as part of CARsgen's ongoing efforts to advance their product pipeline addressing challenges faced by existing CAR T-cell therapies, including improving safety, enhancing efficacy, and reducing treatment costs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。